-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 2, Hongri Pharmaceutical issued an announcement stating that it had recently received a drug registration approval for pramipexole hydrochloride sustained-release tablets (batch number: 2021S00813, 2021S00814) issued by the State Food and Drug Administration
.
Drug information:
Pramipexole hydrochloride is a new generation of non-ergotamine dopamine receptor agonist, with high bioavailability, rapid drug effect, not affected by food, and has a good effect on Parkinson's patients with depression
.
Pramipexole hydrochloride tablets were developed by Boehringer Ingelheim Pharmaceutical Co.
Pramipexole Hydrochloride Sustained-Release Tablets use sustained-release technology to slowly release the drug.